Background: Succinylcholine is one of the most widely used muscle relaxants in clinical anesthesia and emergency medicine. Although the clinical advantages and cardiovascular side effects are well known, its mechanism of action within the human nicotinic cholinergic receptor system remains to be understood. The aim of this study was to investigate the effect of succinylcholine on human muscle and neuronal nicotinic acetylcholine receptor (nAChR) subtypes.
SUCCINYLCHOLINE has been used for more than 50 yr in clinical anesthesia and emergency medicine, and it is still one of the most widely used muscle relaxants. Succinylcholine is composed of two acetylcholine molecules, linked end to end at the acetyl side, and has the potential to exert acetylcholine-like effects at nicotinic acetylcholine receptors (nAChRs).
The nAChRs are members of a neurotransmitter-gated ion channel superfamily. They are composed of five transmembrane subunits with a central cation pore, and the stoichiometry of subunits gives each receptor its unique properties. 1 To date, 17 nicotinic subunits have been cloned in vertebrates: the muscle ␣1, ␤1, ␦, ␥, and subunits and the neuronal ␣2-10 and ␤2-4 subunits. 2 The fetal muscle nAChR consists of two ␣1, one ␤1, one ␦, and one ␥ subunit, but in the adult muscle nAChR, the ␥ subunit is replaced by . 3, 4 The neuronal nAChRs include both of homomeric and heteromeric receptors, with the ␣7-9 subunits forming homomeric nAChRs. The heteromeric receptors are formed by a combination of ␣2-6 and ␤2-4. 1 Although there are many potential combinations of heteromeric neuronal nAChRs, to date, only a few have been found to be of biologic importance. 5, 6 The muscle nAChR is present at the postsynaptic muscle membrane in the neuromuscular junction, whereas the neuronal nAChRs are found both presynaptically and postsynaptically in the central and peripheral nervous system as well as in extraneuronal tissues and cells, such as keratinocytes, muscle, lymphocytes, macrophages, carotid bodies, and neurosecretory cells. 1, 2, 7 There is evidence for nicotinic autoreceptors at the presynaptic terminal in the neuromuscular junction, 8, 9 and it has recently been shown that a block of ␣3␤2 nicotinic receptors produce tetanic fade by interruption of nicotine-mediated autofacilitation of acetylcholine release. 10, 11 The major autonomic ganglionic receptor is ␣3␤4, but functional ␣3␤2 and, to a lesser extent, ␣7 receptors have been detected in ganglionic neurons. 6, 12, 13 In the central nervous system, nAChRs are widespread: ␣4␤2 is the most common nAChR, but ␣3␤2 and ␣7 are also present and functional. 6, 14 In clinical anesthesia, administration of succinylcholine activates the muscle-type nAChR, which is seen as fasciculations of skeletal muscle. This is followed by a block or desensitization, seen as flaccidity. Succinylcholine-induced paralysis lasts for only 5-10 min after a single dose, because of the rapid degradation of succinylcholine to succinylmonocholine and choline by plasma butyrylcholinesterase. 15 In contrast to nondepolarizing neuromuscular blocking agents, succinylcholine does not produce tetanic fade and therefore seems to lack interaction with presynaptic feedback control of transmitter release mediated via the ␣3␤2 nAChR subtype. 8, 10 Succinylcholine has many side effects, of which the cardiovascular effects are more serious. 16 It has been suggested that some cardiovascular side effects caused by succinylcholine arise from an interaction with neuronal nAChRs in autonomic ganglia 17 ; however, this has not been confirmed at the molecular level. Furthermore, the mechanism of action of succinylcholine within the neuromuscular junction is not clear, and the putative interaction with the presynaptic ␣3␤2 nAChR has not been studied previously.
Our aim was to study the effect of succinylcholine on human muscle and neuronal nAChRs expressed in Xenopus oocytes, to describe activation, desensitization, and inhibition of the nAChRs in interaction with the natural ligand, acetylcholine.
Materials and Methods

Clones
The human nAChR subunits ␣1, ␣3-4, ␣7, ␤1, ␤2, ␤4, ␦, and were cloned from a human complementary DNA (cDNA) library. GenBank (Bethesda, MD) access numbers for the cDNA nucleotide sequences are as follows: NM 000079 (␣1), NM 000747 (␤1), NM 000751 (␦), NM 000080 (), HSU62432 (␣3), L35901 (␣4), Y08420 (␣7), Y08415 (␤2), and NM 000750 (␤4). The cDNAs were subcloned into different expression vectors, pBluescript II SK (Ϫ) (Stratagene, La Jolla, CA; ␣7), pKGem (AstraZeneca, Wilmington, DE; ␣1, ␣3, ␤1, ␤2, ␦, and ), and pBSTA (University of California, Irvine, CA; ␣4 and ␤4). Messenger RNA (mRNA) was transcribed in vitro using the mMessage mMachine ® T7 kit (Ambion, Austin, TX) and analyzed using a bioanalyzer (Agilent Technologies, Palo Alto, CA).
Xenopus Oocyte Injection
The study was approved by the local animal ethics committee at Karolinska Institutet, Stockholm, Sweden. Xenopus laevis oocytes were isolated by partial ovariectomy from frogs anesthetized with 0.2% tricaine (3-aminobenzoic acid ethyl ester, 2 g/l added to the water). The incision was sutured, and the animals were monitored during the recovery period before being returned to their tank. The ovaries were mechanically dissected to smaller lumps and digested in OR-2 buffer (82.5 mM NaCl, 2 mM KCl, 2 1 mM MgCl, 5 mM HEPES, pH adjusted to 7.5 with NaOH) containing 1.5 mg/ml collagenase (type 1A; Sigma, St. Louis, MO) for 90 min to remove the follicular epithelia from the oocytes. Injection electrodes were made from 3.5-in Drummond tubes (#3-000-203-G/X; Drummond Scientific Company, Broomall, PA) and pulled using a DMZ-Universal Puller (Zeitz-Instrumente GmbH, Munich, Germany). After 1-24 h, the oocytes were injected with 0.2-18 ng mRNA in a total volume of 30 -40 nl/oocyte. Multiple subunit combinations were injected at a 1:1 ratio (␣1␤1␦ or ␣ x ␤ y ), except for ␣4␤2, where the injection ratio was 1:9. The oocytes were maintained in Leibovitz L-15 medium (Sigma) diluted 1:1 with Millipore (Billerica, MA) filtered double distilled water and 80 g/ml gentamicin, 100 units/ml penicillin and 100 g/ml streptomycin added. Oocytes were incubated at 18°-19°C for 3-7 days after injection before being studied.
Electrophysiologic Recordings
All recordings were performed at room temperature (20°-22°C). During recording, the oocytes were continuously perfused with ND-96 (96.0 mM NaCl, 2.0 mM KCl, 1.8 mM CaCl 2 , 1.0 mM MgCl 2 , 5.0 mM HEPES, pH 7.4 adjusted with NaOH). Oocyte recordings were performed using an integrated system that provides automated impalement of up to eight oocytes studied in parallel with two-electrode voltage clamp, and current measurements were automatically coordinated with fluid delivery throughout the experiment (OpusXpress™ 6000A; Molecular Devices, Union City, CA). Electrodes made from 1.5-mm borosilicate tubes (World Precision Instruments Inc, Sarasota, FL) were pulled using a micropipette puller (PP-83; Narishige Scientific Instrument Lab, Tokyo, Japan) and filled with 3 M KCl (0.5-2.5 M⍀ resistance). The oocytes were voltage clamped at a holding potential of Ϫ60 mV.
Protocol
Oocytes were continuously perfused with ND-96 at a rate of 2 ml/min in a 150-l chamber. Drugs were delivered from a 96-well plate using disposable tips and administrated at a rate of 2 ml/min for the first 2 s, and thereafter at 1 ml/min. In activation experiments, acetylcholine and succinylcholine were applied for 20 s. To determine whether succinylcholine inhibited acetylcholine-induced currents, succinylcholine was coapplied and preapplied with acetylcholine for 55 s before a 20-s application of both acetylcholine and succinylcholine. Between each drug application, there was a 6-min washout period to allow clearance of the drugs and to avoid desensitization of the channels. Before and after each concentration-response experiment, three control responses were recorded using an EC 50 acetylcholine concentration for each receptor subtype to exclude desensitization (precontrol and postcontrol). Experiments were rejected if the postcontrol response was less than 80% of the precontrol response. To adjust for the level of channel expression, the responses in agonist concentration-response experiments were normalized to peak response in each oocyte. For inhibition experiments, re-sponses in each oocyte were normalized to the mean of the second and third acetylcholine precontrols.
Drugs
Succinylcholine, acetylcholine, and butyrylcholinesterase were purchased from Sigma. Chemicals used in buffers were purchased from Sigma or Merck (Nottingham, United Kingdom) unless otherwise stated. Stock solutions of 1 mM acetylcholine and succinylcholine were prepared in ND-96 buffer and frozen. All drugs were then diluted in ND-96 immediately before use.
Data Analysis and Statistics
Off-line analyses were made using Clampfit 9.2 (Molecular Devices). Changes in currents were studied both as peak and net charge responses (area under the curve); however, for ␣7, only net charge analysis was used, as previously described. 18, 19 The baseline current immediately before drug application was subtracted from the response, and the analysis region for peak and net charge analysis was 20 s, i.e., during the time of agonist application. Concentration-response relations for agonists (acetylcholine and succinylcholine) were fitted by nonlinear regression (Prism 4.0; GraphPad, San Diego, CA) to the four parameter logistic equation: Y ϭ Bottom ϩ (Top Ϫ Bottom)/(1 ϩ 10 ((Log EC 50 Ϫ X) * Hill Slope)), wherein Y is the normalized response, X is the logarithm of concentration, and EC 50 is the concentration of agonist eliciting half-maximal response. When succinylcholine-induced inhibition was studied, the same equation was used, and EC 50 was replaced by IC 50 , which is the concentration of antagonist eliciting half maximal inhibition. Unless otherwise stated, data are given as mean Ϯ SEM or 95% confidence interval (CI). Differences in IC 50 values were compared by using paired or unpaired two-tailed Student t test as appropriate. A P value of less than 0.05 was considered significant.
Results
Acetylcholine Concentration-Response Relations for Muscular and Neuronal nAChRs
Acetylcholine produced a concentration-dependent inward current in oocytes injected with muscle-and neuronal-type nAChRs and voltage clamped at Ϫ60 mV ( fig.  1 ), whereas uninjected oocytes did not respond to acetylcholine (data not shown). The responses to acetylcholine of the nAChR subtypes are consistent with previous reports 20 -22 in terms of kinetics and EC 50 values ( fig. 1 and table 1), thus confirming the expression of the individual nAChRs in our receptor model. However, there is a lack of published data for comparison of net charge in human nAChRs, the only exception being for the ␣7 nAChR subtype. 19 As shown in figure 1B , the ␣1␤1␦, ␣3␤4, and ␣4␤2 nAChR concentration-response relations based on net charge analysis correlate well with peak currents, with almost identical EC 50 and Hill coefficients (table 1) . However, the ␣7-subtype nAChR displays unique properties, with very fast desensitization kinetics ( fig. 1A) , which gives a different concentration-response relation depending on whether peak response or net charge was measured ( fig. 1B) . Therefore, EC 50 is significantly lower if calculated from net charge analysis (table 1; P Ͻ 0.0001), in agreement with Papke et al. 18, 19 Succinylcholine and Activation of Muscular nAChRs Succinylcholine produced a concentration-dependent inward current in voltage clamped oocytes expressing adult muscle-type (␣1␤1␦) nAChR ( fig. 1 ). Succinylcholine caused an increasing activation of the ␣1␤1␦ nAChR in concentrations up to 100 M; however, higher concentrations resulted in a reduced response to succinylcholine, likely because of a more rapid channel desensitization by higher succinylcholine concentrations ( fig. 1B ). In most of these succinylcholine concentration-response experiments, we never saw full recovery despite trying both extended washout periods and application of the succinylcholine degrading enzyme, butyrylcholinesterase. Butyrylcholinesterase did not seem to have any effect by itself in the range of 100 -500 M (data not shown). The maximal response to succinylcholine tended to be 30 -40% of that produced by acetylcholine, but detailed comparisons were not performed to calculate efficacy, because the controls did not return at the end of the experiments.
Succinylcholine and Inhibition of Muscular nAChRs
To investigate succinylcholine as a blocker at the ␣1␤1␦-subtype nAChR, succinylcholine was applied before (preapplication) and together with acetylcholine (coapplication). Two concentrations of acetylcholine were studied, 1 M and 5 M. As shown in figure 2A , the concentration-response curve for succinylcholine in the presence of 1 M acetylcholine was similar to the concentration-response curve for succinylcholine alone ( fig. 1B ), but slightly shifted to the right with an EC 50 of 19. 2C ). To calculate an IC 50 for the succinylcholine-dependent decrease in acetylcholine activation, the peak acetylcholine response in presence of succinylcholine minus the base current after 54 s of succinylcholine incubation was normalized to the acetylcholine preapplication current. This yielded an IC 50 of 126 M (95% CI, 47.8 -334 M) and a Hill coefficient of Ϫ1.23 Ϯ 0.93 (n ϭ 11).
As for the succinylcholine activation concentrationresponse relations, the 5 M acetylcholine controls did not recover fully at the end of the experiments in either the coapplication or the preapplication protocol. In contrast, in succinylcholine concentration-response experiments with 1 M acetylcholine, the acetylcholine controls displayed full recovery, indicating receptor desensitization at only repeated higher acetylcholine ap-plications. In previous studies investigating the effect of succinylcholine on the ␣1␤1␦ nAChR, precontrol and postcontrol responses to the agonist have not been measured, 23 or a mean of the controls before and after succinylcholine has been used as reference, and it has not been stated whether the controls where stable during the experiment. 24 
Succinylcholine and Activation of Neuronal nAChRs
In contrast to the muscle-type nAChR, the neuronal types did not respond to succinylcholine in concentrations up to 1 mM ( fig. 1 ). In the range of 1-10 mM succinylcholine, the neuronal ␣3␤2 and ␣3␤4 displayed no succinylcholine activated current, and the ␣4␤2 and ␣7 displayed very small inward currents, with a very low efficacy compared with acetylcholine ( fig. 1A) . The lack of activation of the neuronal nAChRs is not explained by receptor desensitization, inhibition, or oocyte deteriora- tion, because we obtained identical EC 50 acetylcholine control values before and after the experiments.
Succinylcholine and Inhibition of Neuronal nAChRs
To investigate whether succinylcholine inhibits acetylcholine-induced nAChR responses by an interaction with the nAChR site or by succinylcholine-induced desensitization, succinylcholine was given both as a preapplication for 55 s before acetylcholine and as a coapplication with acetylcholine. Concentration-response relations were established with increasing succinylcholine concentrations for each nAChR subtype. For each receptor subtype a fixed acetylcholine concentration was applied (approximately EC 50 ), being 300 M for ␣3␤2 and ␣3␤4, 5 M for ␣4␤2, and 100 M for ␣7. Succinylcholine reversibly and concentration-dependently inhibited acetylcholine-induced currents in the neuronal nAChRs tested ( fig. 3 ). There was no significant difference in IC 50 values whether succinylcholine was preapplied or coapplied with acetylcholine (table 2). The kinetics of the activated current were unchanged with increased succinylcholine concentrations.
To determine the possible mechanism of succinylcholine-induced inhibition of the ␣3␤4 nAChR, we investigated the effect of 150 M succinylcholine on the acetylcholine concentration-response curve. As shown in figure 4 , 150 M succinylcholine reduced acetylcholineinduced currents and peak responses to approximately 70% of the maximal acetylcholine response, and the EC 50 was 304 M (95% CI, 200 -463 M) for acetylcholine and 529 M (95% CI, 83-3,359 M), for acetylcholine plus 150 M succinylcholine (P Ͻ 0.05). Because the succinylcholine-induced inhibition on the ␣3␤4 subtype seems not to be a pure competitive displacement of acetylcholine at the acetylcholine-binding site, we cannot rule out inhibition by channel block or allosteric inhibition.
Discussion
This study demonstrates that succinylcholine desensitizes the muscular ␣1␤1␦ nAChR after initial activation. In contrast, succinylcholine does not activate or desensitize neuronal ␣3␤2, ␣3␤4, ␣4␤2, or ␣7 nAChRs and is moreover a low potency inhibitor of these receptor subtypes.
Succinylcholine concentration-dependently activates the human ␣1␤1␦ nAChR heterologously expressed in Xenopus oocytes with an EC 50 of 10.8 M. This indicates that the human receptor may be slightly more sensitive compared with the mouse receptor, for which an EC 50 value of 33 M 24 has been reported. Succinylcholine has been described as a partial agonist at the muscle nAChR, 23 but because of receptor desensitization after repeated applications of acetylcholine at EC 50 , we were unable to properly compare the potency of succinylcholine with acetylcholine. Coapplication of succinylcholine with 1 and 5 M acetylcholine slightly right shifted the concentration-response activation curve of succinylcholine, and in addition, 5 M acetylcholine produced a decidedly bell-shaped curve. Preapplication of succinylcholine before 5 M acetylcholine concentration-dependently inhibited the response of the ␣1␤1␦ receptor subtype to acetylcholine with an IC 50 of 126 M. Our results support the hypothesis that succinylcholine prevents receptor activation at least partly by desensitization of the ␣1␤1␦ nAChR and are in line with a previous report. 25 We also demonstrate that succinylcholine does not activate the human neuronal nAChRs, ␣3␤2, ␣3␤4, ␣4␤2, or ␣7, in concentrations up to 1 mM and furthermore is a low-potency antagonist at these receptor subtypes. Succinylcholine has previously been shown to be a weak agonist at the rat ␣7 subtype, and furthermore, it has been reported that the rat ␣3␤4 nAChR is not activated by succinylcholine in concentrations up to 1 mM. 23 Interestingly, insertion of a point mutation in the second transmembrane domain of the ␣7 receptor, T244F (Thr to Phe), dramatically changes both biophysical and pharmacologic properties toward those of the muscle receptor. 23 The mutation results in succinylcholine having increased potency and efficacy: Although being a partial agonist at the wild-type ␣7 receptor, succinylcholine is a full agonist at the T244F mutant ␣7 receptor. 23 There is more than 80% homology between human and rodent DNA for a given nAChR subunit. 1 However, a small difference in amino acid sequence at some regions can cause significant changes in biophysical and pharmacologic properties of the receptors. 18, 20, 26 Here, we show that succinylcholine is a partial agonist at the human muscle nAChR; however, we could not calculate the exact efficacy because of apparent receptor desensitization. In contrast, either succinylcholine does not act as an agonist or it is a very weak partial agonist at the neuronal nAChR subtypes. The efficacies were extremely low at these receptor subtypes. Furthermore, no desensitization was seen, because the acetylcholine control responses after the succinylcholine concentrationresponse curve were preserved, and there were no differences in inhibition whether succinylcholine was preapplied or coapplied with acetylcholine. Altogether, succinylcholine does not desensitize the neuronal nAChRs in contrast to the muscle subtype, and the succinylcholine-induced inhibition on the ␣3␤4 subtype seems not to be a pure competitive displacement of acetylcholine at the acetylcholine-binding site. We spec-ulate that inhibition by channel block or allosteric inhibition may also be involved in the inhibition. This has obviously to do with binding site, but this is beyond the scope of this article.
For the neuronal nAChRs, a stoichiometry of 2 ␣ and 3 ␤ has been found when DNA/RNA have been injected into Xenopus oocytes at a ratio of 1:1 (␣:␤). [27] [28] [29] However, it has recently been shown that the ␣4␤2 subtype, when injected in a subunit ratio of 1:9, displays a subtype that is more sensitive to activation and desensitizes more slowly compared with the 1:1 subtype. 30 In addition, human embryonic kidney cells transfected with the human cDNA for the ␣4 and ␤2 subunits displayed the more sensitive subtype if transfected with additional ␤2 subunits or if they were exposed to nicotine or low temperature. 31 In the current study, we investigated this more sensitive ␣4␤2 subtype, and the EC 50 (1.63 M) was similar to those reported in previous studies (1.8 M). 30, 32 We analyzed both peak current and net charge after acetylcholine-induced nAChR activation and restricted the analysis to 20 s (during agonist application) because we believe that this better reflects the effects of agonist and eliminates confounding factors such as rundown and washout conditions. Net charge analysis has convincingly been shown to be a more accurate method to analyze activation of the ␣7 nAChR subtype, which desensitizes very rapidly. 18, 19 For the ␣3␤2, ␣3␤4, ␣4␤2, and ␣1␤1␦ subtypes, the pharmacologic properties are almost identical independent of the method used. The very small difference between peak current and net charge present in the ␣3␤2 nAChR subtype might reflect the rapid initial desensitization of this receptor subtype.
There is a long-standing controversy regarding the mechanism of action of succinylcholine, i.e., whether succinylcholine blocks presynaptic or postsynaptic nAChRs or other structures in the neuromuscular junction. 33 Here, we confirm that succinylcholine initially activates the adult muscle nAChR with an EC 50 of 10.8 M, in reasonable accordance with the clinical EC 50 of 2.6 M. 34 Thereafter, succinylcholine causes a desensitization of the receptor with an apparent IC 50 of 126 M on the acetylcholine response. However, we found that succinylcholine is not an effective competitive antagonist at the human muscle-type nAChR, because succinylcholine, when coapplied with acetylcholine, does not block the receptor. There is a discrepancy between the clinical EC 50 of 2.6 M and the IC 50 in our oocyte preparation, and in addition, nerve stimulation using an in vitro nerve-muscle preparation indicates an EC 50 of 21.3 M for succinylcholine. 35 The latter preparation, however, involves activation through direct innervation rather than through application of exogenous acetylcholine. Based on this, we believe that succinylcholine after initial receptor activation shifts the receptor population toward a desensitized state, rendering fewer receptors available for acetylcholine activation. Because of the high receptor density in the oocytes, there will still be receptors in both open and closed states available for acetylcholine activation, and what we actually measure after succinylcholine preapplication is the "nondesensitized" receptor population in the oocytes. Alternatively, in the neuromuscular junction, activation of approximately 25% of the muscle nAChRs may be sufficient to depolarize and subsequently desensitize the muscle tissue. 36 Given this view, the EC 50 of 10.8 M at the recombinant adult muscle nAChR agrees very closely with the clinical determined EC 50 of 2.6 M. In addition, desensitization of a part of the receptor population on the muscle tissue could be sufficient for inducing a neuromuscular block due to subthreshold muscle depolarization. Finally, we cannot rule out the possibility that accessory proteins associated with the muscle nAChR might be involved, yielding a more potent succinylcholine neuromuscular inhibition in vivo.
Tetanic fade is caused by an interaction with cholinergic presynaptic autoreceptors mediating acetylcholine release from the motor nerve end. 8 For many years, measurement of twitch tension and tetanic fade has served as the base for clinical monitoring of neuromuscular blockade. 37 In contrast to nondepolarizing neuromuscular agents, succinylcholine-induced neuromuscular block is characterized by a lack of tetanic fade. The mechanism behind tetanic fade is not known, and furthermore, it is not known how neuromuscular blocking agents interact with this receptor at a molecular level. It has recently been shown that a block of the presynaptic ␣3␤2 nAChR produces tetanic fade due to inhibition of an acetylcholine-mediated ␣3␤2 autofacilitation. 10 Here, we clearly demonstrate that succinylcholine does not activate the human ␣3␤2 nAChR subtype and, furthermore, blocks the receptor only at very high concentrations of succinylcholine (IC 50 Ͼ 700 M). The finding that succinylcholine has a very low affinity to the ␣3␤2 nAChR is in accordance with the clinical observation that succinylcholine does not cause tetanic fade, and we can, for the first time, provide a molecular explanation and experimental evidence for the lack of tetanic fade in succinylcholine-induced neuromuscular blockade. In addition, the high IC 50 value for succinylcholine at the ␣3␤2 nAChR might also explain the clinical "phase II block," which is seen when succinylcholine has been overdosed and is characterized by tetanic fade and a partial or complete reversal of the block by anticholinesterase. 38, 39 We speculate that this phase II block might in part be due to a block of presynaptic ␣3␤2 nAChRs at high succinylcholine concentrations, because peak succinylcholine plasma concentrations at normal dosage have been shown to be approximately 75.5-143.2 M, 34 and a "phase II block" may develop when succinylcholine is given three to five times the normal dose. 39 However, other receptors as well as other components of the presynaptic nerve terminal can modulate the tetanic fade response, 8, 40, 41 and therefore, involvement of other mechanisms in the "phase II block" in addition to the inhibition of the presynaptic ␣3␤2 nAChR is possible and must be further evaluated. Altogether, our results support the hypothesis that succinylcholine blocks the transmission in the neuromuscular junction by activation and desensitization of the ␣1␤1␦ nAChR, not by an antagonistic effect or block at the presynaptic ␣3␤2 nAChR subtype at normal dosage. Tachyarrhythmias, mainly of ventricular origin, as a side effect of succinylcholine have been suggested to arise as a result of catecholamine release from the adrenal medulla after stimulation of ganglionic nAChRs. 17 The nAChRs present in ganglion are mainly the ␣3␤4 type, but ␣3␤2 and ␣7 nAChR subtypes are also present. 5, 14 Here, we show that none of the ␣3␤2 or ␣3␤4 nAChR subtypes were activated by succinylcholine, and the ␣7 nAChR subtype was activated only at succinylcholine concentrations above 1 mM.
Because succinylcholine is rapidly hydrolyzed to succinylmonocholine and choline, we cannot exclude a possible effect of these breakdown products on neuronal nAChRs. Conformational analysis, however, reveals that succinylmonocholine does not fit very well into the nAChR binding sites. 42 The other breakdown product, choline, is known as a selective ␣7 nAChR agonist, 43, 44 but as such has low potency, with an EC 50 of 400 -500 M, and inhibits the receptor with an IC 50 of greater than 1-10 mM. 18, 45 Interaction of succinylcholine with the M2 muscarinic AChR has also been suggested to cause cardiovascular interactions, but a recent binding study shows that succinylcholine has low affinity for both the M2 and M3 muscarinic AChRs. 46 Interestingly, succinylcholine increases the afferent activity in the cerebral cortex as a result of a stimulation of muscle spindles, leading to an arousal effect on the electroencephalogram and increased cerebral blood flow. 47, 48 The arousal effects on the electroencephalogram have been shown to be similar to those during surgical incision. 49 Therefore, it is possible that some succinylcholine-induced cardiovascular side effects are due to an indirect central activation of the sympathetic nervous system, rather than by a direct interaction with cholinergic receptors in peripheral ganglia.
In conclusion, succinylcholine activates the muscletype nAChR followed by desensitization. Our observation that succinylcholine does not inhibit the presynaptic ␣3␤2 autoreceptor at clinically relevant concentrations provides a possible mechanistic and molecular explanation for the typical lack of tetanic fade in succinylcholine-induced neuromuscular blockade. Finally, cardiovascular side effects (e.g., tachyarrhythmias) of succinylcholine are not mediated via direct activation of the ganglionic ␣3␤4 subtype because succinylcholine does not activate the neuronal nAChRs.
